Drug Details

General Information of the Drug (ID: DR6255)
Name
Synthetic lipid A
Disease Vaccination [ICD-11: N.A.] Investigative [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Saponin      Panax ginseng     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Biological
                    Regulation		 Induction A diverse antibody response
                    In-vivo Model For murine challenge studies, 6 to 8-week-old female C57Bl/6 mice were challenged with 105 plaque forming units (PFU) of WNV via intraperitoneal injection of virus in 0.25 mL total volume.
                    Experimental
                    Result(s)		 A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen.
Target and Pathway
Target(s) Thymidylate synthase (TYMS)  Molecule Info  [3]
References
Reference 1 A structure-function approach to optimizing TLR4 ligands for human vaccines. Clin Transl Immunology. 2016 Nov 2;5(11):e108.
Reference 2 A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen. NPJ Vaccines. 2018 Sep 26;3:39.
Reference 3 Sequential irinotecan hydrochloride/S-1 for S-1-resistant inoperable gastric cancer: A feasibility study. Oncol Lett. 2012 Jan;3(1):89-93.
 Download Picture         KEGG Link